Similarly, activation of ACE2 by systemic injections [243] or intracerebroventricular infusion [244] of the ACE2 activator, diminazene aceturate (DIZE), pre- or post-stroke resulted in beneficial effects without affecting BP or cerebral blood flow (CBF) but the effect was abolished with Mas receptor blockade [244]. This evidence concerns the gene ACE2 and Stroke.